Kisspeptin-10
Get a source-linked, educational explanation from this profile.
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Kisspeptin-10 is listed as reproductive / hypothalamic neuropeptide.
- •HPG-axis stimulation
- •Hypothalamic amenorrhea (research)
- •Sexual arousal (investigational)
Regulatory status: Investigational.
Structure & Properties
Compound: Kisspeptin-10; also known as KP-10, Metastin 45-54.
Pharmacologic class: Reproductive / Hypothalamic Neuropeptide.
Known delivery routes: Intravenous, Subcutaneous (research).
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
KISS1R agonist on hypothalamic GnRH neurons — drives pulsatile GnRH release, restoring LH/FSH and downstream sex hormones; modulates limbic arousal circuits.
- •Restores LH/FSH pulsatility
- •Increases sexual brain activation on fMRI
- •Possible fertility applications
Human Research
Evidence grade: Clinical RCT (Limited)
Clinical RCT (Limited). Phase 1/2 trials at Imperial College & NIH.
Laboratory Research
Phase 1/2 trials at Imperial College & NIH
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
SubQ, morning. Dosing schedules vary by protocol (research).
Potential interactions and combinations to avoid
- •Hormone-sensitive malignancy
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Limited safety data
- •Headache, flushing
- •Unknown long-term endocrine effects
Contraindications
- •Hormone-sensitive cancers
- •Pregnancy unless under fertility care
- •Hormone-sensitive cancer (prostate, breast, ovarian, uterine) without oncology direction
- •Undiagnosed abnormal uterine or vaginal bleeding
- •Pregnancy or possible pregnancy (fetal harm / ovarian hyperstimulation risk)
- •Precocious puberty or unresolved pituitary pathology
- •History of thromboembolism or ovarian hyperstimulation syndrome
- •Seizure disorder or history of epilepsy (lowered seizure threshold reported for some agents)
- •Bipolar disorder, psychosis, or active mania
- •Concurrent MAO inhibitors, stimulants, or serotonergic agents without psychiatric oversight
- •Recent intracranial haemorrhage or unstable neurologic injury
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 0.3–3 nmol/kg (IV, research)
Frequency: Single or pulsatile dosing in studies
Cycling: Not established; protocol-specific.
Intravenous (IV)
Clinician-administered only. Reserved for hospital protocols, senolytics research, or emergency use.
IV catheter / infusion pump. Sterile IV push or slow infusion per protocol. Not for home use.
Subcutaneous (SubQ)
Default route for most research and therapeutic peptides — best absorption for reconstituted powder.
31G × 5/16" insulin syringe (U-100). 100 units = 1 mL. Pinch skin at abdomen (2" from navel), outer thigh, or love handle. Insert at 45–90°. Rotate sites daily to prevent lipohypertrophy. Alcohol-swab site, air-dry, inject slow, hold 5 sec.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •PT-141 / Bremelanotide research stacks
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
What is Kisspeptin-10?
In plain words
Kisspeptin-10 is a short chain of amino acids that acts as a hormone signal. The body responds by releasing brain signals in pulses that help control reproductive hormones. Researchers study it to stimulate this hormone system and investigate absent menstrual periods linked to reduced hormone signaling from the brain. It is not FDA-approved; trial evidence and safety data are limited, reported risks include headache and flushing, and long-term hormone effects are unknown.
Technical definition
Kisspeptin-10 (KP-10; Metastin 45–54) is a ten-amino-acid reproductive neuropeptide and an agonist of KISS1R on hypothalamic gonadotropin-releasing hormone (GnRH) neurons. It drives pulsatile GnRH release, stimulating luteinizing hormone (LH), follicle-stimulating hormone (FSH), and downstream sex-hormone production, and also modulates limbic arousal circuits. It is investigational and not FDA-approved, with limited randomized clinical trial evidence for hypothalamic–pituitary–gonadal axis stimulation and research in hypothalamic amenorrhea.
Function
Dosing
Recommended Time of Day
Morning, fasted.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- IV — clinician only — Antecubital vein or central line. Not for home administration.
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Flank / love handle — Lateral fat pad above the hip. Good rotation site when the abdomen is tender.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Not established; protocol-specific.
Timing & Interactions
- ·Hormone-sensitive malignancy
- ·PT-141 / Bremelanotide research stacks
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Kisspeptin-10 and sync them to Vial Lab.
Benefits
- ·Restores LH/FSH pulsatility
- ·Increases sexual brain activation on fMRI
- ·Possible fertility applications
Risks
- ·Limited safety data
- ·Headache, flushing
- ·Unknown long-term endocrine effects
Contraindications
- ·Hormone-sensitive cancers
- ·Pregnancy unless under fertility care
- ·Hormone-sensitive cancer (prostate, breast, ovarian, uterine) without oncology direction
- ·Undiagnosed abnormal uterine or vaginal bleeding
- ·Pregnancy or possible pregnancy (fetal harm / ovarian hyperstimulation risk)
- ·Precocious puberty or unresolved pituitary pathology
- ·History of thromboembolism or ovarian hyperstimulation syndrome
- ·Seizure disorder or history of epilepsy (lowered seizure threshold reported for some agents)
- ·Bipolar disorder, psychosis, or active mania
- ·Concurrent MAO inhibitors, stimulants, or serotonergic agents without psychiatric oversight
- ·Recent intracranial haemorrhage or unstable neurologic injury
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
Investigational
Veterinary Use (Pets)
No established veterinary protocol for Kisspeptin-10. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.